Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Income towards Parent Company: 2017-2024

Historic Income towards Parent Company for DiaMedica Therapeutics (DMAC) over the last 8 years, with Dec 2024 value amounting to -$24.4 million.

  • DiaMedica Therapeutics' Income towards Parent Company fell 26.40% to -$2.5 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$10.6 million, marking a year-over-year decrease of 85.72%. This contributed to the annual value of -$24.4 million for FY2024, which is 26.12% down from last year.
  • Per DiaMedica Therapeutics' latest filing, its Income towards Parent Company stood at -$24.4 million for FY2024, which was down 26.12% from -$19.4 million recorded in FY2023.
  • In the past 5 years, DiaMedica Therapeutics' Income towards Parent Company registered a high of -$12.3 million during FY2020, and its lowest value of -$24.4 million during FY2024.
  • For the 3-year period, DiaMedica Therapeutics' Income towards Parent Company averaged around -$19.2 million, with its median value being -$19.4 million (2023).
  • Data for DiaMedica Therapeutics' Income towards Parent Company shows a maximum YoY slumped of 41.72% (in 2023) over the last 5 years.
  • DiaMedica Therapeutics' Income towards Parent Company (Yearly) stood at -$12.3 million in 2020, then declined by 10.58% to -$13.6 million in 2021, then declined by 0.62% to -$13.7 million in 2022, then slumped by 41.72% to -$19.4 million in 2023, then decreased by 26.12% to -$24.4 million in 2024.